tecovirimat · Siga Technologies · NDA 208627, 214518
Tpoxx
Earliest generic entry, as listed · earliest of 2 marketed strengths
4 Sep 2031
Other strengths are listed to 8 Aug 2032.
Blocked by patent: US 7737168, US 7737168. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 9 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11890270 | use U-2346 | 8 Aug 2032 |
| US 7737168 | use U-3377 | 4 Sep 2031 |
| US 7737168 | use U-2346 | 4 Sep 2031 |
| US 10576165 | product | 2 Aug 2031 |
| US 9233097 | product | 2 Aug 2031 |
| US 9907859 | use U-3377 | 2 Aug 2031 |
| US 12433868 | product | 23 Mar 2031 |
| US 9339466 | substance, product | 23 Mar 2031 |
| US 8039504 | product | 23 Jul 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 208627 · 001 · RLD | capsule, oral | 200MG | 8 Aug 2032 |
| 214518 · 001 · RLD | solution, intravenous | 200MG/20ML (10MG/ML) | 4 Sep 2031 |